Three-dimensional culture method enhances the therapeutic efficacies of tonsil-derived mesenchymal stem cells in murine chronic colitis model

Eun Mi Song1, Yang Hee Joo1, A. Reum Choe1, Yehyun Park1, Chung Hyun Tae1, Ji Teak Hong1, Chang Mo Moon1, Seong-Eun Kim1, Hye-Kyung Jung1, Ki-Nam Shim1, Kyung-Ah Cho1, Inho Jo3 & Sung-Ae Jung1*

Tonsil-derived mesenchymal stem cells (TMSCs) showed therapeutic effects on acute and chronic murine colitis models, owing to their immunomodulatory properties; therefore, we evaluated enhanced therapeutic effects of TMSCs on a murine colitis model using three-dimensional (3D) culture method. The expression of angiogenic factors, VEGF, and anti-inflammatory cytokines, IL-10, TSG-6, TGF-β, and IDO-1, was significantly higher in the 3D-TMSC-treated group than in the 2D-TMSC-treated group (P < 0.05). At days 18 and 30 after inducing chronic colitis, disease activity index scores were estimated to be significantly lower in the 3D-TMSC-treated group than in the colitis control (P < 0.001 and P < 0.001, respectively) and 2D-TMSC-treated groups (P = 0.022 and P = 0.004, respectively). Body weight loss was significantly lower in the 3D-TMSC-treated group than in the colitis control (P < 0.001) and 2D-TMSC-treated groups (P = 0.005). Colon length shortening was significantly recovered in the 3D-TMSC-treated group compared to that in the 2D-TMSC-treated group (P = 0.001). Histological scoring index was significantly lower in the 3D-TMSC-treated group than in the 2D-TMSC-treated group (P = 0.002). These results indicate that 3D-cultured TMSCs showed considerably higher therapeutic effects in a chronic murine colitis model than those of 2D-cultured TMSCs via increased anti-inflammatory cytokine expression.

Inflammatory bowel disease (IBD) is a chronic relapsing disease that includes Crohn's disease (CD) and ulcerative colitis (UC). The incidence and prevalence of IBD in Asian countries have increased owing to westernization of societies1,2. In Korea, the incidence and prevalence of IBD have continued to increase over the past three decades. In a recently published population-based cohort study, the incidence rates of CD and UC per 100,000 inhabitants were reported to increase from 0.06 and 0.29, in 1986–1990, to 2.44 and 5.82, in 2011–2015, respectively3.

Although the pathogenesis of IBD remains unclear, the development of IBD is thought to be associated with complex mechanisms that involve innate genetic susceptibility, aberrant immune response, gut microbiota, and other environmental factors, including westernized diet and smoking4–6. Over the past decades, immunosuppressive and newly developed biological agents, including anti-tumor necrosis factor α (TNF-α) agents and small molecules such as anti-integrin agent, have been employed for the treatment of IBD, in addition to conventional therapies that involve 5-aminosalicylic acid and corticosteroids, thereby improving the treatment outcomes of IBD. However, despite these improvements in IBD treatment, up to 40% of patients with IBD failed to show ideal therapeutic results7,8.

Recently, mesenchymal stem cells (MSCs) therapy has been introduced as a potential therapeutic alternative for several diseases, including IBD, owing to their immunosuppressive and tissue-regenerative properties9,10. Tonsil-derived MSCs (TMSCs) have been proposed as a new source of MSCs owing to their rapid proliferation rate and easy availability11–13. In our previous studies, intraperitoneal (IP) administration of TMSCs in dextran
sulfate sodium (DSS)-induced acute and chronic murine colitis models demonstrated therapeutic efficacy in terms of lowering disease activity index (DAI) scores, colon length recovery, and by decreasing the expression of pro-inflammatory cytokines [14,15]. Additionally, TMSC-conditioned medium showed similar efficacy as TMSCs in acute and chronic murine colitis models, thereby suggesting that TMSCs exhibit therapeutic effects through the anti-inflammatory mechanism.

To improve the therapeutic effect of MSCs, several strategies, including pretreatment with pro-inflammatory cytokines or hypoxic condition, have been evaluated [16]. The effect of these pretreatments is thought to stimulate MSCs to maintain anti-inflammatory properties in inflamed tissues under in vivo stress conditions. Recently, a three-dimensional (3D) culture method was reported to improve survival and enhance the therapeutic properties of MSCs [17]. In an acute kidney injury model, 3D-cultured human adipose tissue-derived MSCs (ADSCs) showed increased secretion of anti-apoptotic and anti-oxidative cytokines when compared with 2D-cultured MSCs, thereby demonstrating enhanced survival and therapeutic effects. However, the therapeutic effects of 3D-cultured TMSCs in a colitis model remain unclear.

In this study, we aimed to evaluate whether 3D-culture method could improve the therapeutic efficacy of TMSCs in a chronic murine colitis model.

Results

**In vitro.** Increased expression of anti-inflammatory cytokines and growth factors in 3D-cultured TMSCs. The average size of in vitro 3D-cultured TMSC spheroids on days 1, 2, and 3 was 182.4 ± 8.3, 169.4 ± 7.7, and 154.1 ± 4.9 μm, respectively (Fig. 1). The size of the spheroids significantly decreased with time after 24 h of 3D culture (Supplementary Figure 1). To evaluate the molecular characteristics of 3D-cultured TMSCs, we analyzed the expression of inflammatory and anti-inflammatory cytokines using qRT-PCR and compared them with the results obtained for 2D-cultured TMSCs. The expression of anti-inflammatory cytokines, including interleukin (IL)-10 and TNF-stimulated gene 6 (TSG-6), was significantly higher in 3D-cultured TMSCs than in 2D-cultured TMSCs (P < 0.005, Fig. 2). Additionally, the expression level of vascular endothelial growth factor (VEGF) in the 3D-cultured TMSCs was significantly higher than that in the 2D-cultured TMSCs (P < 0.001). The expression levels of C-X-C motif chemokine receptor 4 (CXCR4) and indoleamine 2,3-dioxygenase-1 (IDO-1) in the 3D-
cultured TMSCs were significantly higher than those in the 2D-cultured TMSCs (P < 0.005). In contrast, the expression level of stromal cell-derived factor 1 (SDF-1) in the 3D-cultured TMSCs was significantly lower than that in the 2D-cultured TMSCs (P < 0.005; Fig. 2).

In vivo. Therapeutic effects of 3D-cultured TMSCs on chronic murine colitis models. We evaluated the therapeutic effects of 3D-cultured TMSCs in the DSS-induced chronic colitis murine model. All mice, except those belonging to the normal control group, exhibited bloody diarrhea on day 3 post-chronic colitis induction and body weight loss on day 6 post-chronic colitis induction. Macroscopic DAI scores based on stool consistency, body weight loss, and fecal blood in the 3D-TMSC-treated group were significantly lower than those in the DSS + PBS control group or DSS + HEK control group on days 18 and 30 post-chronic colitis induction [day 18, 3.7 ± 1.9 vs. 7.2 ± 2.2 (P = 0.001) or 7.6 ± 3.5 (P = 0.013); day 30, 2.5 ± 1.5 vs. 8.4 ± 3.8 (P = 0.001) or 7.6 ± 4.4 (P = 0.010); Fig. 3]. Similarly, the DAI scores in the 3D-TMSC-treated group were significantly lower than those in the 2D-TMSC-treated group on days 18 and 30 post-chronic colitis induction [day 18, 3.7 ± 1.9 vs. 5.7 ± 2.7 (P = 0.022); day 30, 2.5 ± 1.5 vs. 5.8 ± 3.9 (P = 0.004); Fig. 3]. Additionally, the body weight loss (%) in the 3D-TMSC-treated group was significantly lower than that in the DSS + PBS control, DSS + HEK control and 2D-TMSC-treated groups on day 30 post-chronic colitis induction [+ 3.5 ± 12.6% vs. − 22.6 ± 15.5% (P = 0.001), − 17.6 ± 19.9% (P = 0.027), and − 12.0 ± 15.2% (P = 0.005); Fig. 4].

Furthermore, colitis-associated colon length shortening in the 3D-TMSC-treated group (79.1 ± 7.5 mm) was significantly lower than that in the DSS + PBS control (67.1 ± 5.5 mm) and DSS + HEK control groups (66.0 ± 2.2 mm) (P < 0.005 for all; Fig. 5). The recovery of colon shortening in the 3D-TMSC-treated group (79.1 ± 7.5 mm) was also significantly higher than that in the 2D-TMSC-treated group (70.3 ± 6.2 mm; P = 0.001; Fig. 5).

Cytokine expression in the colonic tissues of mice belonging to the 3D-TMSC-treated group. We measured the mRNA expression levels of inflammatory cytokines in the colon tissues of mice in each group. The mRNA expression levels of pro-inflammatory cytokines, including IL-1B, IL-17, and IL-6, were significantly down-regulated in the 3D-TMSC-treated group when compared with those in the colitis control group (P = 0.001, P = 0.001, and P = 0.024, respectively, Fig. 6). Although IL-1B, IL-17, and IL-6 levels were lower in the 3D-TMSC-treated group than in the 2D-TMSC-treated group, the difference was not statistically significant, except for
IL-17 (P = 0.036, Fig. 6). We also measured the protein expression levels of cytokines in the colon tissue using a cytokine array (Fig. 7). Consistent with the downregulated mRNA levels of IL-1β, the protein levels of IL-1β were significantly downregulated in the 3D-TMSC-treated group. However, the level of IL-17 was not significantly different between the groups. The levels of other pro-inflammatory cytokines, including TNF-α and IL-1α, and chemokines associated with immune cell activation, such as keratinocyte chemoattractant (KC; CXCL-1) and monocyte chemoattractant protein-1 (MCP-1) were significantly downregulated on treatment with 3D-TMSCs.

**Histopathological improvement after 3D-cultured TMSCs treatment.** As shown in Fig. 8, the colonic structure in the DSS-induced chronic colitis model was disrupted and characterized by the loss of crypts, diffuse mucosal and submucosal edema, infiltration of mononuclear cells, and ulcerations. The histological scoring index (HSI) values, which indicate the severity and extent of inflammation and crypt damage, in the 3D-TMSC-treated group (5.7 ± 2.8) were significantly lower than those in the colitis control group (5.7 ± 2.8; P = 0.01; Fig. 8). Histological analysis revealed that treatment with 3D-cultured TMSCs mitigated the DSS-induced severe inflammatory cell infiltration, loss of crypts, and ulceration (Fig. 8). The HSI values in the 3D-TMSC-treated group (5.7 ± 2.8) were also significantly lower than those in the 2D-TMSC-treated group (7.6 ± 2.7; P = 0.002).

**TMSC localization in the peritoneum of mice using immunofluorescence.** White spherical aggregates were observed in the euthanized mice. We assumed that the injected TMSCs formed an aggregate in the perito-
neal space of mice. Some aggregates were adjacent to the mouse intestine, whereas other aggregates were not attached to any organ and were observed in the omentum and mesentery (Fig. 9a). Spheroids were observed in the 3D-TMSC-treated group but not in the 2D-TMSC-treated group. To confirm the location of TMSCs in vivo, the cells were tracked with anti-human nuclear antigen antibodies using immunofluorescence. Fluorescence microscopy analysis revealed that the previously observed aggregates were stained with green-colored anti-human nuclear antigen antibodies, which indicated that the transplanted 3D-cultured TMSCs formed a cluster in the peritoneum irrespective of colon inflammation (Fig. 9b). In addition, the expression levels of human DNA in the peritoneal lavage fluid of each groups and aggregates were measured. The expression levels of human DNA were the highest in the aggregates, followed by the peritoneal lavage fluid of 3D-TMSC-treated and 2D-TMSC-treated groups (Fig. 9c). This indicates that these whitish aggregates in the mouse peritoneal cavity comprise TMSCs.

Discussion
In the present study, we evaluated the therapeutic effects of 3D-cultured TMSCs and compared them with those of 2D-cultured TMSCs in a chronic murine colitis model. 3D-cultured TMSC treatment ameliorated the clinical symptoms, including fecal blood, body weight loss, and shortening of colon length in a chronic murine colitis model. Additionally, histological improvement was achieved with 3D-cultured TMSCs, which was not observed through 2D-cultured TMSC treatment. Moreover, we showed that the 3D-culture method could enhance the expression of anti-inflammatory cytokines and growth factors in TMSCs and the survival of TMSCs in vivo after transplantation.

Initially, MSCs were thought to infiltrate into inflamed tissues and engage in tissue regeneration by differentiating into mature intestinal epithelial cells. However, recently published studies showed that the paracrine effect is a more important mechanism of MSCs irrespective of their location in vivo. Although MSCs are considered as a promising new therapeutic modality in various diseases, including IBD, clinical trials showed controversial outcomes. Reduced cell viability of MSCs after in vivo transplantation has limited its usability. Moreover, to maintain effective paracrine activity of MSCs, the transplanted cells should endure harsh microenvironments (e.g., oxidative, inflammatory, and hypoxic conditions), which reduce the rate of cell engraftment and survival. Recently, 3D-culture method has been evaluated as a modality to improve the efficacy of MSC therapy. More recently, organoid culture methods, which are physiologically more relevant, have been developed to overcome the shortcomings of MSC therapy.
In our previous studies, we evaluated the therapeutic effect of TMSCs in acute and chronic colitis models. IP injection of TMSCs significantly ameliorated DSS-induced colitis; however, no histologically significant effects were observed. Additionally, in acute and chronic colitis models, TMSC-conditioned medium showed similar therapeutic efficacy as TMSCs. However, histological improvements were not achieved through treatment with TMSC-conditioned medium. Moreover, we tried to improve the therapeutic efficacy of TMSCs pretreated with ascorbic acid and metformin, however, we could not achieve the desired results (data not shown).

In the current study, the 3D-culture method showed significant enhancement in the therapeutic efficacy of TMSCs in addition to histological improvement.

The efficacy of 3D-culture method for MSC therapy has been evaluated for several disease models, including those of inflammation, ischemic injury, and cancer. In a previous study, 3D-cultured ADSCs showed enhanced inhibitory effects on liver cancer cells when compared with 2D-cultured or sphere-cultured ADSCs. Xu et al. reported that 3D-culture method enhanced cell survival and paracrine effect of MSCs, thereby showing therapeutic effects on acute kidney injury model. Additionally, a recently published study demonstrated that this enhanced cell function and cell viability of MSCs by 3D-culture method are mediated via decreased reactive oxygen species production and autophagy activation. Molendijk et al. investigated the therapeutic effect of intraluminally-injected 3D-cultured bone marrow-derived MSCs (BMSCs) in a DSS-induced acute colitis model. However, this study only evaluated the therapeutic effect of 3D-cultured BMSCs, administered through limited injection methods, in an acute colitis model, and comparison with 2D-cultured MSCs was not appropriately performed.

In the current study, we evaluated enhanced therapeutic effects in a chronic colitis model, which are clinically similar to chronic human IBD.

Enhanced cell survival of 3D-cultured TMSCs was demonstrated in our study, which corresponds with the results obtained in the previous studies. Upon tracking the location of transplanted 2D- and 3D-cultured TMSCs on day 31, 3D-cultured TMSCs, which were injected at least 14 days before euthanizing the mice, were observed to form aggregates in the peritoneum independently of the inflamed colon, however, this effect was not observed upon 2D-cultured TMSC administration. Interestingly, the transplanted 3D-cultured TMSCs were detected in the peritoneum, but not incorporated in the colon tissues, implying that the therapeutic effects of 3D-cultured TMSCs were not caused by gut-homing. Our results are in accordance with a previous study by Sala et al., who reported that intraperitoneally injected BMSCs do not localize in the intestine, instead they form aggregates in the peritoneum and produce cytokines. The mechanisms underlying the survival of transplanted human 3D-TMSCs in immunocompetent mice have not been elucidated. However, long-term survival of human

![Figure 6.](https://doi.org/10.1038/s41598-021-98711-4)
MSCs in mice has also been reported in previous studies. Dhada et al. examined the viability of MSCs using the nanoprobe method and reported that 5% of transplanted human MSCs were detected in mice at day 10 post-transplantation\(^2\). Ning et al. tracked the labeled human MSCs in the mouse pulmonary fibrosis injury model for up to day 23 post-transplantation\(^2\). Although spontaneous cell death occurs after the transplantation of 3D-TMSCs, this process may be delayed by the immunomodulatory function of 3D-TMSCs, which is associated with the secretion of immune-modulatory cytokines, including IDO-1, TSG-6, and transforming growth factor β (TGF-β). In addition, the expression level of CXCR4 in the 3D-cultured TMSCs was higher than that in the 2D-cultured TMSCs. CXCR4 is reported to increase the viability and migration of MSCs\(^3,4\). Therefore, CXCR4 may play a critical role in the enhanced survival of 3D-TMSCs.

Paracrine secretion of therapeutic cytokines, not tissue regeneration by gut-homing, may play an important role in the treatment mechanism of TMSCs. Although the exact mechanism of 3D-cultured TMSC-mediated attenuation of chronic murine colitis is unclear, enhanced paracrine secretion of these beneficial cytokines may be involved in imparting this effect. In our study, the expression of anti-inflammatory cytokines, including IL-10 and TSG-6, was significantly increased via 3D-culture method (P < 0.05). In a previous study, TSG-6 was reported to be a key cytokine in MSC therapy and promoted the expansion of regulatory macrophages that expressed IL-10 and inducible nitric oxide synthase, and reduced serum levels of interferon-α, IL-6, and TNF-α\(^5\). Moreover, in experimental myocardial infarction model, treatment with MSCs reduced tissue damage by producing TSG-6\(^6\). Importantly, TMSCs highly expressing TSG-6 showed therapeutic effect in an acute graft-versus-host disease (GVHD) mouse model\(^7\). In our study, TSG-6 production was markedly increased by 3D-culture method, thereby, enhancing the therapeutic effect of TMSCs. Moreover, the expression levels of cytokines associated with immunomodulatory effects, including TGF-β and IDO-1, were significantly upregulated in the 3D-cultured TMSCs. Additionally, the expression levels of IL-10, TSG-6, TGF-β, and IL-17 were downregulated in the colon tissues of the 3D-TMSC-treated group, which may be due to the production of cytokines associated with immune-regulatory functions, such as TSG-6, TGF-β, and IDO-1. The upregulated expression of VEGF in the 3D-cultured TMSCs may also promote the repair of damaged intestinal mucosa by enhancing TMSC migration and proliferation and accelerating the growth of vessels\(^8\).

In summary, the present study demonstrated that 3D-cultured TMSCs significantly ameliorated chronic colitis by reducing clinical symptoms, recovery of colon shortening, and histological improvements. We further demonstrated enhanced survival of 3D-cultured TMSCs in the peritoneum. Additionally, we demonstrated that the increased paracrine effect of anti-inflammatory cytokines, including IL-10, TSG-6, TGF-β, and IDO-1, may play a critical role in mediating the therapeutic effect of 3D-cultured TMSCs. Thus, the 3D-culture method provided a novel approach to enhance TMSC function and, thereby, could have therapeutic applications in IBD.
Methods

Isolation and expansion of TMSCs. Subjects aged less than 18 years were recruited in this study. Written informed consent was obtained from a parent and/or patients’ legal guardians for studies on tonsil tissues. This study was approved by the Ewha Womans University Medical Center institutional review board (ECT 11–53–02). All experiments were performed in accordance with the institutional ethical guidelines and the Declaration of Helsinki. All tonsil tissues used in this study were obtained from a single donor. TMSCs were isolated and cultured as described in our previous studies. Briefly, tonsil tissues were obtained during tonsillectomy in patients younger than 10 years of age. The tonsil tissues were minced and digested in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 210 U/mL collagenase type I (Invitrogen) and 10 g/mL DNase (Sigma-Aldrich, St. Louis, MO, USA) at 37 °C for 30 min. Digested tissues were washed using Dulbecco’s modified Eagle’s medium–high glucose (DMEM-HG; Welgene, Daegu, South Korea) supplemented with 20% fetal bovine serum (FBS; Invitrogen), and washed again using DMEM-HG supplemented with 10% FBS. From the prepared tonsil tissues, we isolated mononuclear cells using Ficoll-Paque (GE Healthcare, Little Chalfont, UK) density gradient centrifugation. The isolated mononuclear cells were then cultured in cell culture plates, and non-adherent cells were removed after 8 h of seeding. The remaining adherent cells were further cultured for 2 weeks and passaged. The passaged cells (hereafter referred to as TMSCs) were stored in liquid nitrogen for future experiments. The MSC characteristics of TMSCs according to the minimal criteria for defining multipotent mesenchymal stromal cells were confirmed in our previous study. In brief, the immunophenotypic surface marker assay results revealed that TMSCs were negative for hematopoietic cell markers, such as CD14, CD34, and CD45 and positive for common MSC markers, such as CD73, CD90, and CD105. In addition, cell-specific staining assays were performed to examine the differentiation of TMSCs into adipocytes, chondrocytes, and osteoblasts. TMSCs could differentiate into these three cell types upon induction with commercially available differentiation media.
Figure 9. Localization of 3D-cultured TMSCs in the peritoneum of mice analyzed using immunofluorescence staining. (a) Image of the gross morphology of aggregates in the peritoneum of the mouse. (b) One aggregate was adjacent to the mouse colon. Fluorescence microscopy revealed that the previously observed aggregate was stained with green-colored anti-human nuclear antigen antibody. (c) The levels of human DNA in the peritoneal lavage fluid of each groups and aggregates. 3D, three-dimensional; TMSCs, tonsil-derived mesenchymal stem cells; H&E, hematoxylin–eosin; HNA, human nuclear antigen.

Induction of chronic colitis using DSS in mice. The animal models used for the experiment were 7-week-old C57BL/6 male mice (Orient Bio Co., Ltd., Sungnam, Gyeonggi, Korea) with an average weight of 20–22 g. The mice were acclimatized for 7 days in a standardized environment at the facility of the Ewha Womans University Medical Research Institute prior to the experiment. Day and night conditions were provided at 12 h intervals, and temperature (23 ± 2 °C) and humidity (45–55%) were set to appropriate levels. Experiment and procedures were approved and all experiments were performed in accordance with experimental research...
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for cytokine expression. Values were compared between the groups.

Crypt damage, and the damaged portion (%) of the whole colon were evaluated. Finally, the averages of the HSI determining the expression of pro-inflammatory cytokines, namely, IL-1β, IL-6, TNF-α, IL-17, IL-4, IL-5, IL-10, CXCR4, SDF-1, TGF-β, IDO-1, α-1 chain of type 1 collagen (COL1A1), VEGF, B-cell CLL/lymphoma 2 (Bcl-2), Bcl-2 associated X (Bax), and TSG-6 in TMSC lysates using the QuantStudio 3 real-time PCR system (Applied Biosystems, Waltham, MA, USA) (Supplementary Table 1). Detailed procedures are described in Supplementary Methods.

Experimental design. In the chronic colitis model, mice were randomly assigned to five groups: (1) normal control (n = 10), (2) DSS + PBS control (n = 17), (3) DSS + HEK control (n = 5), (4) 2D-TMSC-treated group (n = 17), and (5) 3D-TMSC-treated group (n = 18). The DSS + PBS group was intraperitoneally injected with phosphate-buffered saline (PBS) on days 6 and 16 post-chronic colitis induction. The DSS + HEK control group was intraperitoneally injected with HEK293 cells (1 × 10⁶ cells) on days 6 and 16 post-chronic colitis induction. Meanwhile, the 2D-TMSC-treated and 3D-TMSC-treated groups were intraperitoneally injected with 1.0 × 10⁶ TMSCs/500 μL PBS on days 6 and 16 post-chronic colitis induction. We used StemFIT 3D micro 853 wells and 3D-cultured spheroids of TMSCs were formed using StemFIT 3D micro 853 wells (Microft, Hanamsi, Korea). One plate had 853 wells, each of 400 μm in size, and 1.0 × 10⁶ cells/mL were cultured in a plate. Therefore, each spheroid comprised approximately 1200 TMSCs. TMSCs from passages 6 to 8 were used to form spheroids. After culturing, spheroids with a size of approximately 200 μm were formed. The expression levels of Nanog, Sox2, and Oct4 (stem cell markers) in the 3D-cultured TMSCs were comparable to those in the 2D-cultured TMSCs. This suggests that 3D-cultured TMSCs maintained the MSC phenotype (Supplementary Figure 2). We used 3D-cultured TMSCs on day 1 of spheroid formation. The size of the 3D-cultured TMSCs was measured on days 1, 2, and 3. The qRT-PCR analysis was performed to determine the expression levels of IL-4, IL-5, IL-10, CXCR4, SDF-1, TGF-β, α-1 chain of type 1 collagen (COL1A1), VEGF, B-cell CLL/lymphoma 2 (Bcl-2), Bcl-2 associated X (Bax), and TSG-6 in TMSC lysates using the QuantStudio 3 real-time PCR system (Applied Biosystems, Waltham, MA, USA) (Supplementary Table 1). Detailed procedures are described in Supplementary Methods.

Assessment of therapeutic effect of TMSCs. DAI scoring. For each group, the body weight and DAI scores, including weight change, stool consistency, and occult or fecal blood, were determined as previously reported (Supplementary Table 2). Measuring colon length and histopathological scoring. On day 31 of chronic colitis induction, mice were euthanized with CO₂ gas inhalation, and colon specimens were acquired from the proximal and distal parts of the dissected colon and fixed with 10% formalin, followed by paraffin sectioning and hematoxylin–eosin (H&E) staining. Two specimens from each proximal and distal colon were evaluated using a previously reported histological colitis scoring system (Supplementary Table 3). The severity and extent of inflammation, the level of crypt damage, and the damaged portion (%) of the whole colon were evaluated. Finally, the averages of the HSI values were compared between the groups.

Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for cytokine expression. qRT-PCR for determining the expression of pro-inflammatory cytokines, namely, IL-1β, IL-6, TNF-α, IL-17, and the anti-inflammatory cytokine IL-10 in colonic tissues was performed using the QuantStudio 3 real-time PCR system (Applied Biosystems, Waltham, MA, USA). Detailed procedures are described in the Supplementary methods.

Cytokine array analysis. The levels of cytokines in the colonic tissue were analyzed using the Proteome Profiler Mouse Cytokine Array Panel A kit (R&D Systems, Minneapolis, MN, USA), following the manufacturer’s instructions. In brief, the tissues were lysed using radioimmunoprecipitation assay buffer (containing protease inhibitor cocktail). The protein concentration in the lysate was measured using a BCA Protein assay kit (Thermo Scientific, Waltham, MA, USA). Tissue protein diluted in array buffer was incubated with the ready-to-use pre-coated array membranes overnight at 4 °C on a rocking platform shaker. The membrane was washed and incubated with streptavidin–horseradish peroxidase (HRP) buffer for 30 min. Next, the membrane was washed and incubated with the Chemi Reagent mixture at 23–27 °C for 1 min. The membrane was analyzed using the LAS-300 system (Fujifilm, Tokyo, Japan). Dot density was analyzed using Multi Gauge 3.0.

Immunofluorescence analysis for visualizing TMSC localization and determination of human DNA expression levels in the mouse peritoneal cavity cells. Colon specimens were fixed as paraaffin blocks and 4 μm wide sections were resected. After deparaffinization and hydration, the specimens were blocked with mouse IgG reagent using a mouse on mouse (M. O. M) kit (Vector Laboratories, CA, USA). TMSCs were then stained with human nuclear antigen monoclonal antibody (MyBioSource, CA, USA). After fluorescence staining with Avidin DCS (Vector Laboratories, CA, USA), the specimens were mounted with Vectashield phalloidin (Vector Laboratories, CA, USA), and observed using fluorescence microscopy. The expression levels of human DNA in the peritoneal lavage fluid of each treated groups and aggregates were measured. The mice were euthanized and sprayed with 70% ethanol. The outer skin of the peritoneum was dissected using scissors and forceps and gently pulled back to expose the inner skin surrounding the abdominal cavity. The peritoneal lavage fluid was collected by injecting 5 mL of ice-cold saline into the peritoneal cavity.
using a 26 G needle. The collected cell suspension was centrifuged at 1500 rpm for 8 min. The supernatant was discarded and the cell pellet was stored at − 70 °C. Total RNA was extracted from the isolated intraperitoneal cells using TRIzol Reagent (Ambion, Life Technologies, Carlsbad, CA, USA). cDNA was synthesized using the Moloney murine leukemia virus reverse transcriptase (M-MLV RT) kit (Promega, Fitchburg, WI, USA). The qRT-PCR analysis was performed using the human GAPDH-specific primer set (Forward 5′-CTAAGCcTGAG ACGGGGAAG-3′ and Reverse 5′-CGGCCCACTTTGATTGAGA-3′) to confirm the presence of human-origin cells among intraperitoneal cells.

**Statistical analysis.** The measured values of all experimental results are expressed as mean ± standard deviation (s.d.). Comparisons between two groups, including parametric or non-parametric analyses, were performed using an unpaired Student’s t-test or Mann–Whitney U test, respectively. P values less than 0.05 were considered statistically significant. All statistical analyses were performed using IBM SPSS version 22.0 (IBM Corp., Armonk, NY, USA).

**Data availability**
The raw data supporting the conclusions of this article will be made available by the corresponding author, without undue reservation, to any qualified researcher.

Received: 8 March 2021; Accepted: 7 September 2021
Published online: 01 October 2021

**References**

1. Ng, S. C. et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. *Gastroenterology* **145**, 158–165.e152. https://doi.org/10.1053/j.gastro.2013.04.007 (2013).

2. Ananthakrishnan, A. N., Kaplan, G. G. & Ng, S. C. Changing global epidemiology of inflammatory bowel diseases: Sustaining health care delivery into the 21st century. *Clin. Gastroenterol. Hepatol.* **18**, 1252–1260. https://doi.org/10.1016/j.cgh.2020.01.028 (2020).

3. Park, S. H. et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986–2015. *J. Crohns Colitis* **13**, 1410–1417. https://doi.org/10.1093/ecco-jcc/jju081 (2019).

4. Khor, B., Gardet, A. & Xavier, R. J. Genetics and pathogenesis of inflammatory bowel disease. *Nature* **474**, 307–317. https://doi.org/10.1038/nature10209 (2011).

5. Kobayashi, Y. et al. Association of dietary fatty acid intake with the development of ulcerative colitis: A multicenter case-control study in Japan. *Inflamm. Bowel Dis.* **27**, 617–628. https://doi.org/10.1093/ibd/izaa140 (2021).

6. Lakatos, P. L. et al. Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. *Inflamm. Bowel Dis.* **19**, 1010–1017. https://doi.org/10.1097/MIB.000000000000202c (2013).

7. Ben-Horin, S., Kopylov, U. & Chowers, Y. Optimizing anti-TNF treatments in inflammatory bowel disease. *Autoimmun. Rev.* **13**, 24–30. https://doi.org/10.1016/j.autrev.2013.06.002 (2014).

8. Papamichael, K. et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: Evolution in the definition and management of primary nonresponse. *Inflamm. Bowel Dis.* **21**, 182–197. https://doi.org/10.1097/MIB.0000000000000202 (2015).

9. Flores, A. L., Gómez-Gómez, G. J., Masedo-González, Á. & Martínez-Montiel, M. P. Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?. *World J. Stem Cells* **7**, 343–351. https://doi.org/10.4252/wjsc.v7.i12.343 (2015).

10. Liang, J. et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. *Gut* **61**, 468–469. https://doi.org/10.1136/gutjnl-2011-300803 (2012).

11. Janjani, S. et al. Human palatine tonsil: A new potential tissue source of multipotent mesenchymal progenitor cells. *Arthritis Res. Ther.* **10**, R83. https://doi.org/10.1186/ar2459 (2008).

12. Xu, Y., Shi, T., Xu, A. & Zhang, L. 3D spherical culture enhances survival and therapeutic capacities of MSCs injected into ischemic kidney. *J. Cell Mol. Med.* **20**, 1203–1213. https://doi.org/10.1111/jcmm.12651 (2016).

13. Oh, S. T. et al. Application of tonsil-derived mesenchymal stem cells in tissue regeneration: Concise review. *Stem Cells** 37**, 1252–1260. https://doi.org/10.1002/stem.3058 (2019).

14. Song, E. M. et al. The therapeutic efficacy of tonsil-derived mesenchymal stem cells in dextran sulfate sodium-induced acute murine colitis model. *Korean J. Gastroenterol.* **69**, 119–128. https://doi.org/10.4166/kjg.2017.69.2.119 (2017).

15. Yu, Y. et al. Therapeutic potential of tonsil-derived mesenchymal stem cells in dextran sulfate sodium-induced experimental murine colitis. *PloS ONE* **12**, e0183141. https://doi.org/10.1371/journal.pone.0183141 (2017).

16. Yu, Y. et al. Preconditioning with interleukin-1 beta and interferon-gamma enhances the efficacy of human umbilical cord blood-derived mesenchymal stem cells-based therapy via enhancing prostaglandin E2 secretion and indoleamine 2,3-dioxygenase activity in dextran sulfate sodium-induced colitis. *J. Tissue Eng. Regen. Med.* **13**, 1792–1804. https://doi.org/10.1002/term.2930 (2019).

17. Kim, H. J. et al. Three-dimensional spheroid formation of cryopreserved human dental follicle-derived stem cells enhances pluripotency and osteogenic properties. *Tissue Eng. Regen. Med.* **16**, 513–523. https://doi.org/10.1080/17407921.2019.1649745 (2019).

18. Mishra, R., Dhawan, P., Srivastava, A. S. & Singh, A. B. Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy. *World J. Stem Cells* **12**, 1050–1066. https://doi.org/10.4252/wjsc.v12.i10.1050 (2020).

19. Sala, E. et al. Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine. *Gastroenterology* **149**, 163–176.e120. https://doi.org/10.1053/j.gastro.2015.03.013 (2015).

20. Fähn, Z. The effects of hypoxia on the immune-modulatory properties of bone marrow-derived mesenchymal stromal cells. *Stem Cells Int.* **2019**, 2509606. https://doi.org/10.1155/2019/2509606 (2019).

21. Regmi, S. et al. Enhanced viability and function of mesenchymal stromal cell spheroids is mediated via autophagy induction. *Autophagy* https://doi.org/10.1080/15548627.2020.1850608 (2020).

22. Yoo, J. J., Cho, C. S. & Jo, I. Applications of organoids for tissue engineering and regenerative medicine. *Tissue Eng. Regen. Med.* **17**, 729–730. https://doi.org/10.1089/term.2019.00035x (2020).

23. Lee, K. E. et al. The efficacy of conditioned medium released by tonsil-derived mesenchymal stem cells in a chronic murine colitis model. *PloS ONE* **14**, e0225739. https://doi.org/10.1371/journal.pone.0225739 (2019).

24. Lee, E. J. et al. Spherical bullet formation via E-cadherin promotes therapeutic potency of mesenchymal stem cells derived from human umbilical cord blood for myocardial infarction. *Mol. Ther.* **20**, 1424–1433. https://doi.org/10.1038/mt.2012.58 (2012).

25. Bicer, M., Cottrell, G. S. & Widera, D. Impact of 3D cell culture on bone regeneration potential of mesenchymal stromal cells. *Stem Cell Res. Ther.* **12**, 31. https://doi.org/10.1186/s13287-020-02094-8 (2021).
26. Xie, H. et al. 3D-cultured adipose tissue-derived stem cells inhibit liver cancer cell migration and invasion through suppressing epithelial-mesenchymal transition. *Int. J. Mol. Med.* 41, 1385–1396. https://doi.org/10.1007/s41598-021-98711-4 (2018).

27. Molendijk, I. et al. Intraluminal injection of mesenchymal stromal cells in spheroids attenuates experimental colitis. *J. Crohns Colitis* 10, 953–964. https://doi.org/10.1093/ijccjm/ljw047 (2016).

28. Yang, S. K., Loftus, E. V. Jr. & Sandborn, W. J. Epidemiology of inflammatory bowel disease in Asia. *Inflamm. Bowel Dis.* 7, 260–270. https://doi.org/10.1097/00054725-200108000-00013 (2001).

29. Ning, X. et al. Long-term in vivo CT tracking of mesenchymal stem cells labeled with Au@BSA@PLL nanotracers. *Nanoscale* 11, 20932–20941. https://doi.org/10.1039/c9nr05637h (2019).

30. Zheng, J. et al. Preconditioning of umbilical cord-derived mesenchymal stem cells by rapamycin increases cell migration and ameliorates liver ischaemia/reperfusion injury in mice via the CXCR4/CXCL12 axis. *Cell Proliif.* 52, e12546. https://doi.org/10.1111/cpr.12546 (2019).

31. Liu, H. et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. *PLoS ONE* 7, e34608. https://doi.org/10.1371/journal.pone.0034608 (2012).

32. Lee, R. H. et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. *Cell Stem Cell* 5, 54–63. https://doi.org/10.1016/j.stem.2009.05.003 (2009).

33. Cho, K. A. et al. Conditioned medium from human palatine tonsil mesenchymal stem cells attenuates acute graft-vs.-host disease in mice. *Mol. Med. Rep.* 19, 609–616. https://doi.org/10.3892/mmr.2018.9659 (2019).

34. Song, S. Y., Chung, H. M. & Sung, J. H. The pivotal role of VEGF in adipose-derived-stem-cell-mediated regeneration. *Expert Opin. Biol. Ther.* 10, 1529–1537. https://doi.org/10.1517/14712598.2010.522987 (2010).

35. Yu, Y. et al. Characterization of long-term in vitro culture-related alterations of human tonsil-derived mesenchymal stem cells: Role for CCN1 in replicative senescence-associated increase in osteogenetic differentiation. *J. Anut.* 225, 510–518. https://doi.org/10.1111/joa.12229 (2014).

36. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 8, 315–317. https://doi.org/10.1080/14653240600855905 (2006).

37. Rya, K. H. et al. Tonsil-derived mesenchymal stromal cells: Evaluation of biologic, immunologic and genetic factors for successful banking. *Cytotherapy* 14, 1193–1202. https://doi.org/10.1016/j.jcyt.2012.07.008 (2012).

38. Peric de Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. *Br. J. Pharmacol.* 177, 3617–3624. https://doi.org/10.1111/bph.15193 (2020).

39. Stevecv, L., Pavli, P., Husband, A., Ramsay, A. & Doe, W. F. Dextran sulphate sodium-induced colitis is ameliorated in interleukin 4 deficient mice. *Gut* 52, 713–719. https://doi.org/10.1136/gut.52.5.713 (2003).

Acknowledgements
This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (NRF-2019R1A2C1002526), SK Chemical Research Fund of The Korean Society of Gastroenterology.

Author contributions
Planning and conducting the study: J.S.A., S.E.M., Y.H.J.; Conducting the experiment: Y.H.J., S.E.M.; Interpreting the data: P.Y., C.A.R., T.C.H., M.C.M., H.J.T., S.E.K., J.H.K., S.K.N.; Drafting the manuscript: S.E.M.; Critical revision of the manuscript for important intellectual content: C.K.A., J.I.H., J.S.A.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-98711-4.

Correspondence and requests for materials should be addressed to S.-A.J.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021